All
Feasibility of Post-Transplant Velcade in Mantle Cell Lymphoma Encourages Further Study
December 10th 2018Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.
Curcumin and Vitamin D Treatment May Stabilize Disease in Patients with CLL and SLL
December 7th 2018In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.
FDA Approves Frontline Tecentriq Regimen for NSCLC
December 7th 2018The Food and Drug Administration has approved Tecentriq (atezolizumab) for use in combination with Avastin (bevacizumab), carboplatin, paclitaxel, the treatment combination known as ABCP, for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Two Are Better Than One: Alternating Chemoimmunotherapy Regimens May Benefit Those with MCL
December 7th 2018A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.
My Candle in the Wind: Remembering a Loss to Hodgkin's Lymphoma
December 5th 2018Especially during holiday seasons, we remember loved ones who are not with us. Even long after they have passed, we can cherish old memories and even make new ones with the help of social media. Recently I learned something sweet about my brother John, who died of Hodgkin's lymphoma decades ago, from a high school friend I never knew about.
Immunotherapy Regimen Granted Priority Review in Small Cell Lung Cancer
December 5th 2018The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Lynparza Significantly Delays Progression in Advanced Ovarian Cancer, Study Finds
December 4th 2018Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.